146 related articles for article (PubMed ID: 33074189)
1. Flash Electroretinography Parameters and Parkinson's Disease.
Netser R; Demmin DL; Dobkin R; Goldstein A; Roché M; Netser Zernik A; Silverstein SM
J Parkinsons Dis; 2021; 11(1):251-259. PubMed ID: 33074189
[TBL] [Abstract][Full Text] [Related]
2. [Preliminary clinical observations of retina injury in alkaline ocular trauma patients].
Xie X; Zhang HL; Wu WY; Feng Y
Zhonghua Yan Ke Za Zhi; 2020 Jul; 56(7):514-518. PubMed ID: 32842333
[No Abstract] [Full Text] [Related]
3. People with current major depression resemble healthy controls on flash Electroretinogram indices associated with impairment in people with stabilized schizophrenia.
Demmin DL; Netser R; Roché MW; Thompson JL; Silverstein SM
Schizophr Res; 2020 May; 219():69-76. PubMed ID: 31375317
[TBL] [Abstract][Full Text] [Related]
4. Altered Outer Retinal Structure, Electrophysiology and Visual Perception in Parkinson's Disease.
Tran KKN; Lee PY; Finkelstein DI; McKendrick AM; Nguyen BN; Bui BV; Nguyen CTO
J Parkinsons Dis; 2024; 14(1):167-180. PubMed ID: 38189711
[TBL] [Abstract][Full Text] [Related]
5. Visuomotor control in patients with Parkinson's disease.
Chen J; Ho SL; Lee TM; Chang RS; Pang SY; Li L
Neuropsychologia; 2016 Jan; 80():102-114. PubMed ID: 26529488
[TBL] [Abstract][Full Text] [Related]
6. Correlations among multifocal electroretinography and optical coherence tomography findings in patients with Parkinson's disease.
Unlu M; Gulmez Sevim D; Gultekin M; Karaca C
Neurol Sci; 2018 Mar; 39(3):533-541. PubMed ID: 29349656
[TBL] [Abstract][Full Text] [Related]
7. Non-motor symptoms in treated and untreated Chinese patients with early Parkinson's disease.
Zhang H; Gu Z; An J; Wang C; Chan P
Tohoku J Exp Med; 2014 Feb; 232(2):129-36. PubMed ID: 24573063
[TBL] [Abstract][Full Text] [Related]
8. Initiation of medications for Parkinson's disease: a qualitative description.
Shin JY; Habermann B
J Clin Nurs; 2016 Jan; 25(1-2):127-33. PubMed ID: 26420046
[TBL] [Abstract][Full Text] [Related]
9. Electroretinographic anomalies in schizophrenia.
Demmin DL; Davis Q; Roché M; Silverstein SM
J Abnorm Psychol; 2018 May; 127(4):417-428. PubMed ID: 29745706
[TBL] [Abstract][Full Text] [Related]
10. Lack of association of morphologic and functional retinal changes with motor and non-motor symptoms severity in Parkinson’s disease.
Cubo E; López Peña MJ; Diez-Feijo Varela E; Pérez Gil O; Garcia Gutierrez P; Araus González E; Prieto Tedejo R; Mariscal Pérez N; Armesto D
J Neural Transm (Vienna); 2014 Feb; 121(2):139-45. PubMed ID: 24078167
[TBL] [Abstract][Full Text] [Related]
11. Nonmotor symptoms evolution during 24 months of bilateral subthalamic stimulation in Parkinson's disease.
Dafsari HS; Silverdale M; Strack M; Rizos A; Ashkan K; Mahlstedt P; Sachse L; Steffen J; Dembek TA; Visser-Vandewalle V; Evans J; Antonini A; Martinez-Martin P; Ray-Chaudhuri K; Timmermann L;
Mov Disord; 2018 Mar; 33(3):421-430. PubMed ID: 29465787
[TBL] [Abstract][Full Text] [Related]
12. Antiparkinsonian drugs as potent contributors to nocturnal sleep in patients with Parkinson's disease.
Taguchi S; Koide H; Oiwa H; Hayashi M; Ogawa K; Ito C; Nakashima K; Yuasa T; Yasumoto A; Ando H; Fujikake A; Fukuoka T; Tokui K; Izumi M; Tsunoda Y; Kawagashira Y; Okada Y; Niwa JI; Doyu M
PLoS One; 2021; 16(7):e0255274. PubMed ID: 34320022
[TBL] [Abstract][Full Text] [Related]
13. Retinal function following transpupillary thermotherapy for occult choroidal neovascularization in age-related macular degeneration: a short-term study by focal electroretinography.
Pirozzi E; Manganelli C; Piccardi M; Minnella A; Fadda A; Ziccardi L; Coccimiglio F; Falsini B
Acta Ophthalmol Scand; 2006 Feb; 84(1):27-35. PubMed ID: 16445436
[TBL] [Abstract][Full Text] [Related]
14. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes.
Rascol O; Fitzer-Attas CJ; Hauser R; Jankovic J; Lang A; Langston JW; Melamed E; Poewe W; Stocchi F; Tolosa E; Eyal E; Weiss YM; Olanow CW
Lancet Neurol; 2011 May; 10(5):415-23. PubMed ID: 21482191
[TBL] [Abstract][Full Text] [Related]
15. Continuous quantitative monitoring of physical activity in Parkinson's disease patients by using wearable devices: a case-control study.
Cai G; Huang Y; Luo S; Lin Z; Dai H; Ye Q
Neurol Sci; 2017 Sep; 38(9):1657-1663. PubMed ID: 28660562
[TBL] [Abstract][Full Text] [Related]
16. Impact of newer pharmacological treatments on quality of life in patients with Parkinson's disease.
Gallagher DA; Schrag A
CNS Drugs; 2008; 22(7):563-86. PubMed ID: 18547126
[TBL] [Abstract][Full Text] [Related]
17. Effects of dopaminergic replacement therapy on motor speech disorders in Parkinson's disease: longitudinal follow-up study on previously untreated patients.
Rusz J; Tykalová T; Klempíř J; Čmejla R; Růžička E
J Neural Transm (Vienna); 2016 Apr; 123(4):379-87. PubMed ID: 26843071
[TBL] [Abstract][Full Text] [Related]
18. Does pattern electroretinogram spatial tuning alteration in Parkinson's disease depend on motor disturbances or retinal dopaminergic loss?
Peppe A; Stanzione P; Pierantozzi M; Semprini R; Bassi A; Santilli AM; Formisano R; Piccolino M; Bernardi G
Electroencephalogr Clin Neurophysiol; 1998 Apr; 106(4):374-82. PubMed ID: 9741766
[TBL] [Abstract][Full Text] [Related]
19. Electrophysiological signs of retinal dopamine deficiency in recently diagnosed Parkinson's disease and a follow up study.
Ikeda H; Head GM; Ellis CJ
Vision Res; 1994 Oct; 34(19):2629-38. PubMed ID: 7975301
[TBL] [Abstract][Full Text] [Related]
20. Lack of independent mood-enhancing effect for dopaminergic medications in early Parkinson's disease.
Espay AJ; Foster ED; Coffey CS; Uribe L; Caspell-Garcia CJ; Weintraub D;
J Neurol Sci; 2019 Jul; 402():81-85. PubMed ID: 31125734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
